Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab: Efficacy and Safety Results from the Phase 3b/4 LEVEL UP Study. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 6, p. s451, 2024. DOI: 10.25251/skin.8.supp.451. Disponível em: https://skin.dermsquared.com/skin/article/view/3041. Acesso em: 5 apr. 2025.